CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer.
Yanna LiZhixiong WangPeng GaoDanping CaoRunyu DongMenglin ZhuYao FeiXueliang ZuoJuan CaiPublished in: Journal of translational medicine (2024)
Our results demonstrated that circRHBDD1 promoted GC immune escape by upregulating the expression of PD-L1 and reprogramming T cell-mediated immune response. Inhibition of circRHBDD1 expression could potentially enhance the response of GC patients to immunotherapy, thus improving treatment outcomes. Additionally, the development of a nanodrug delivery system provides a feasible approach for future clinical applications.
Keyphrases
- poor prognosis
- immune response
- binding protein
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- long non coding rna
- dendritic cells
- patient reported outcomes
- current status
- cell proliferation
- toll like receptor
- mass spectrometry
- pi k akt
- simultaneous determination
- tandem mass spectrometry